AstraZeneca PLC (BCBA:AZN)

Market Cap	417.73T
Revenue (ttm)	79.66T
Net Income (ttm)	12.88T
Shares Out	n/a
EPS (ttm)	8,248.60
PE Ratio	32.43
Forward PE	18.60
Dividend	795.69 (1.11%)
Ex-Dividend Date	Aug 8, 2025

Volume	36
Average Volume	228
Open	71,125
Previous Close	70,750
Day's Range	70,550 - 71,425
52-Week Range	36,850 - 79,800
Beta	n/a
RSI	55.88
Earnings Date	Feb 10, 2026

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Crestor, Seloken, Lokelma, Roxadustat, Andexxa, Wainua, Symbicort, Fasenra, Pulmicort, Breztri/Trixeo, Saphnelo, Tezspire, Airsupra, Ultomiris, Soliris, Strensiq, Koselugo, Kanuma, Atacand, Plendil, Modip, Splendil, Munobal, Flodil, Komboglyze, Qtern, B...

• Industry: Pharmaceutical Preparations
• Founded: 1992
• Employees: 94,300
• Stock Exchange: Buenos Aires Stock Exchange
• Ticker Symbol: AZN

Financial Performance

In 2024, AstraZeneca's revenue was $54.07 billion, an increase of 18.03% compared to the previous year's $45.81 billion. Earnings were $7.04 billion, an increase of 18.14%.

Financial numbers in USD